文献速递神经肿瘤

IDH突变2级胶质瘤仅手术后长期结局

Long-Term Outcomes in Patients With Isocitrate Dehydrogenase-Mutated Grade 2 Glioma Who Never Received Adjuvant Oncological Treatment After Upfront Mapping-Based Surgical Resection.
PubMed 文献 · Neurosurgery · 2025-09-19

本研究分析111例IDH突变2级胶质瘤患者,均接受基于术中定位的首次手术切除后从未接受辅助肿瘤治疗。中位随访8.3年,总生存率100%,97.3%患者KPS≥80,80.6%继续工作。结论提示对选择性的低级别胶质瘤患者,术后单纯监测可行。

要点

  • IDH突变2级胶质瘤术后未接受辅助治疗者长期总生存率100%
  • 平均切除程度98.1%,76.6%达到超全或全切除,无永久性神经功能缺损
  • 生长速率≤1 mm/年的稳定患者术后可考虑单纯监测

核心结论

  • 对经术中定位手术切除的IDH突变2级胶质瘤患者,术后单纯监测可作为一种选择,尤其适用于达到(超)边缘切除且肿瘤生长缓慢者,即使年龄超过40岁。

研究设计与样本

  • 回顾性连续队列研究,纳入111例IDH突变2级胶质瘤患者,均由同一作者使用术中定位进行首次手术,且至少随访3年、末次评估时未接受任何肿瘤治疗。
  • 比较两组:组1为稳定或进展极慢(生长速率≤1 mm/年)并单纯监测者;组2为复发(生长速率>1 mm/年)包括接受再手术者。

主要发现

  • 平均随访8.3±4年,总生存率100%。
  • 末次评估时108例(97.3%)KPS≥80,79例(80.6%)继续工作。
  • 平均切除程度98.1±4.7%,85例(76.6%)为超全/全切除,平均残留肿瘤体积0.6±1.6 cm³。
  • 49例(44.1%)接受再手术(共164次切除),术后无功能恶化。
  • 组1患者年龄更大(P=.0009)、术前肿瘤体积更小(P=.028)、切除程度更高(P=.002)、超全/全切除率更高(P=.024)、术后肿瘤体积更小(P=.0009);再手术者生长速率更高(P<.0001)。

关键数值与推荐

  • 生长速率≤1 mm/年定义为稳定或进展极慢,>1 mm/年定义为复发。
  • 术前平均肿瘤体积21.4±17.2 cm³,术后平均KPS 96.7±5.3,92例(93.8%)恢复工作。
  • 病理类型:IDH突变星形细胞瘤60例(54%),少突胶质细胞瘤51例。

临床怎么用

  • 对于IDH突变2级胶质瘤,若术中定位下实现(超)全切除且术后生长速率缓慢,可考虑单纯监测而非立即辅助治疗。
  • 再手术在无功能恶化情况下可行,但生长速率>1 mm/年者再手术风险更高。

局限性

  • 回顾性单中心连续队列,非随机对照,选择偏倚可能存在。
  • 样本量111例,随访时间虽长但部分患者随访可能不完整。
  • 未报告无进展生存期等详细肿瘤学结局。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVES: Patients with low-grade glioma (LGG) have a long-life expectancy, especially after initial surgery. However, no report specifically investigated LGG patients who underwent only resection without oncological therapy. In this study, long-run outcomes were analyzed in LGG patients who never received adjuvant treatment after upfront mapping-based surgical resection. METHODS: Inclusion criteria were patients operated on by the author using intraoperative mapping for isocitrate dehydrogenase-mutated grade 2 gliomas, followed at least 3 years with no oncological treatment at last evaluation. Two groups were compared: group 1 comprising stable LGG or progressing very slowly (growth rate ≤1 mm/year) with a simple monitoring and group 2 comprising recurrent LGG (growth rate >1 mm/year), including patients who underwent reoperation(s). RESULTS: This consecutive series included 111 patients (49 men, mean age 37.3 ± 10.4 years) with epilepsy in 74 cases (66.7%). The mean Karnofsky Performance Scale (KPS) score was 96.5 ± 5.7; 98 patients (88.3%) worked before surgery. The mean preoperative tumor volume (TV) was 21.4 ± 17.2 cm 3 . The mean postoperative KPS score was 96.7 ± 5.3 (no permanent deficit) with 92 patients who returned to work (93.8%). The mean extent of resection was 98.1 ± 4.7%, with 85 supratotal/total resections (76.6%)-mean residual TV of 0.6 ± 1.6 cm 3 . There were 60 isocitrate dehydrogenase-mutant astrocytomas (54%) and 51 oligodendrogliomas. Forty-nine patients (44.1%) underwent reoperation(s) without deterioration after 164 resections. The mean follow-up was 8.3 ± 4 years with an overall survival rate of 100%. At final evaluation, 108 patients (97.3%) had a KPS score ≥80 and 79 patients (80.6%) continued to work. In group 1, patients were older ( P = .0009) with lower preoperative TV ( P = .028), greater extent of resection ( P = .002), higher rate of (supra)total resections ( P = .024), and lower postoperative TV ( P = .0009). The growth rate was higher in patients with reoperation ( P < .0001). CONCLUSION: Postoperative simple monitoring can be considered in selected patients after upfront mapping-based surgery for LGG, especially when (supra)marginal resection was achieved in tumor with slow growth rate, even after the age of 40 years.

来源:Neurosurgery,查看原文。版权归原作者所有。

引用

  1. Duffau H. Long-Term Outcomes in Patients With Isocitrate Dehydrogenase-Mutated Grade 2 Glioma Who Never Received Adjuvant Oncological Treatment After Upfront Mapping-Based Surgical Resection. Neurosurgery. 2025. PMID: 40970733. doi:10.1227/neu.0000000000003760

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。